Aug 16th 2012 - Edison Investment Research today published a report on IXICO (IXI.L, LSE:IXI, LON:IXI) entitled "Commercial Formulation Required". In summary, the report says:
Phytopharm is seeking to strengthen its partnering package for its Parkinson’s disease candidate Cogane with the start of an important Phase I bioavailability study with solid dose capsule formulations. Results by end 2012/early 2013 are significant to making Cogane, currently being tested as a slightly less convenient liquid formulation, more commercially viable and attractive to potential partners. However, Cogane’s true magnetism is ultimately dependent on top-line results in February 2013 from the Confident-PD Phase II study, a binary event for Phytopharm. We maintain our rNPV of £48m while noting that success in both trials and securing a partner would raise our valuation to £83m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »